A new meningococcal B vaccine for adolescents and adults: characteristics and methods of use

Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease.N Engl J Med. 2001 May 3;344(18):1378-88. DOI: 10.1056/NEJM200105033441807.

Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, Zhujun S, Bhutta ZA, Abramson J.Global epidemiology of invasive meningococcal disease.Popul Health Metr. 2013 Sep 10;11(1):17. doi: 10.1186/1478-7954-11-17.

Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Sáfadi MA. The changing and dynamic epidemiology of meningococcal disease.Vaccine. 2012 May 30;30 Suppl 2:B26-36. doi: 10.1016/j.vaccine.2011.12.032.

Bexsero SmPC.

Available on: https://www.ema.europa.eu/documents/product-information/bexsero-epar-product-information_en.pdf

Trumenba SmPC.

Available on: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004051/WC500228995.pdf

Ultimo accesso: 08/10/2018

McNeil LK, Donald RGK, Gribenko A, French R, Lambert N, Harris SL Jones TR, Li S, Zlotnick G, Vogel U, Claus H, Abad R, Vazquez JA, Borrow R, Findlow J, Taha MK, Deghmane AE, Caugant DA, Kriz P, Musilek M, Wang X, Vuong J, Mayer LW, Pride MW, Jansen KU, Anderson AS. Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine. MBio. 2018 Mar 13;9(2). doi: 10.1128/mBio.00036-18.

Biagini M, Spinsanti M, De Angelis G Tomei S, Ferlenghi I, Scarselli M, Rigat F, Messuti N, Biolchi A, Muzzi A, Anderloni G, Brunelli B, Cartocci E, Buricchi F, Tani C, Stella M, Moschioni M, Del Tordello E, Colaprico A, Savino S, Giuliani MM, Delany I, Pizza M, Costantino P, Norais N, Rappuoli R, Masignani V. Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. Proc Natl Acad Sci USA 2016; 113(10): 2714-9. doi: 10.1073/pnas.1521142113

Zlotnick GW, Jones TR, Liberator P, Hao L, Harris S, McNeil LK, Zhu D, Perez J, Eiden J, Jansen KU, Anderson AS. The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease. Hum Vaccin Immunother. 2015;11(1):5-13. doi: 10.4161/hv.34293

Donald RGK, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, Perez JL, Eiden JJ, Jansen KU, Anderson AS. Meningococcal serogroup B vaccines: Estimating breadth of coverage. Hum Vaccin Immunother. 2017;13(2):255-65. doi: 10.1080/21645515.2017.1264750.

Vesikari T, Ostergaard L, Diez-Domingo J, Wysocki J, Flodmark CE, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Crowther G, Perez JL. Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents. J Pediatric Infect Dis Soc 2016;5:152–60. doi: 10.1093/jpids/piv039

Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015, MMWR Morb Mortal Wkly Rep June 12, 2015 / 64(22);608-612

Disponibile su: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6422a3.htm

Ultimo accesso: 08/10/2018

Patton ME, Stephens D, Moore K, MacNeil JR. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine — Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep 2017;66:509–513.

Disponibile su: http://dx.doi.org/10.15585/mmwr.mm6619a6 .

Ultimo accesso: 08/10/2018

Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Singleton JA, Curtis CR, MacNeil J, Markowitz LE, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years–United States, 2014. MMWR Morb Mortal Wkly Rep 2015;64:784–92.

Beeslaar J, Absalon J, Balmer P, Srivastava A, Maansson R, York LJ, Perez JL. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal

serogroup B vaccine, in adolescents and young adults. Vaccine. 2018 Jun

;36(28):4004-4013. doi: 10.1016/j.vaccine.2018.05.060

Shirley, M., & Taha, M.-K. MenB-FHbp Meningococcal Group B Vaccine (Trumenba®): A Review in Active Immunization in Individuals Aged ≥ 10 Years. Drugs, 2018; 78(2), 257–268. doi:10.1007/s40265-018-0869-7